Travere Therapeutics Ownership | Who Owns Travere Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Travere Therapeutics Ownership Summary


Travere Therapeutics is owned by 5.13% institutional investors, 0.70% insiders, and 94.16% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 10.31% of TVTX shares. Delaware Small Cap Core I is the top mutual fund, with 4.42% of its assets in Travere Therapeutics shares.

TVTX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockTravere Therapeutics5.13%0.70%94.16%
SectorHealthcare Stocks 279.18%10.62%-189.80%
IndustryBiotech Stocks 63.96%10.74%25.30%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de8.02M10.31%$139.68M
Blackrock7.64M9.86%$62.84M
Armistice capital7.36M9.46%$128.18M
Vanguard group6.74M8.67%$117.45M
Rock springs capital management lp4.97M6.39%$86.64M
Macquarie group4.26M5.48%$74.20M
Janus henderson group4.06M5.22%$70.69M
State street3.51M4.53%$28.86M
Morgan stanley3.49M4.50%$28.69M
Viking global investors lp2.90M3.73%$50.55M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Rock springs capital management lp4.97M3.30%$86.64M
Kynam capital management, lp1.80M2.71%$32.31M
Parkman healthcare partners1.12M2.59%$19.47M
Birchview capital, lp138.00K2.15%$2.47M
Exome asset management118.02K1.88%$2.11M
Armistice capital7.36M1.75%$128.18M
Eversept partners, lp816.25K1.49%$14.63M
Knott david m jr228.00K1.44%$3.97M
Emerald advisers2.13M1.43%$37.03M
Emerald mutual fund advisers trust1.10M1.17%$19.19M

Top Buyers

HolderShares% AssetsChange
Janus henderson group4.06M0.04%4.03M
Viking global investors lp2.90M0.16%2.90M
Bnp paribas arbitrage, snc1.21M0.01%1.21M
Fmr1.12M0.00%972.60K
Jennison associates816.40K0.01%816.40K

Top Sellers

HolderShares% AssetsChange
State street3.51M0.00%-3.10M
Woodline partners lp2.11M0.25%-2.23M
Finepoint capital lp---1.78M
Balyasny asset management---1.29M
Logos global management lp---1.00M

New Positions

HolderShares% AssetsChangeValue
Viking global investors lp2.90M0.16%2.90M$50.55M
Bnp paribas arbitrage, snc1.21M0.01%1.21M$21.07M
Jennison associates816.40K0.01%816.40K$14.22M
Abrdn392.00K0.01%392.00K$6.83M
Impax asset management group300.00K0.02%300.00K$5.23M

Sold Out

HolderChange
Toronto dominion bank-3.00
Nelson, van denburg & campbell wealth management group-14.00
Global retirement partners-19.00
Pnc financial services group-20.00
Innealta capital-28.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202511-94.74%4,535,953-95.23%50.03%5-96.12%3-94.12%
Dec 31, 2024107-42.47%35,070,340-57.58%450.40%66-30.53%23-58.93%
Sep 30, 20241855.11%82,651,760-6.09%1060.82%96-6.80%5414.89%
Jun 30, 2024176-1.68%88,008,8780.38%1130.88%10310.75%47-7.84%
Mar 31, 20241792.29%87,677,4492.46%1130.91%933.33%51-5.56%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Delaware Small Cap Core I3.45M4.42%-21.39K
Macquarie Small Cap Core I3.56M4.01%111.60K
Vanguard Total Stock Mkt Idx Inv2.85M3.21%94.34K
Aviva Investors GlConvtAbsRet I USD Acc2.20M2.88%-229.35K
Vanguard US Total Market Shares ETF2.51M2.82%-
iShares Russell 2000 ETF2.16M2.43%1.06K
SPDR® S&P Biotech ETF1.64M1.84%2.12K
HBM Healthcare Investments AG Ord1.32M1.48%-309.55K
Janus Henderson Global Life Sciences D1.25M1.41%335.59K
Janus Henderson Global Life Sciences1.25M1.41%701.24K

Recent Insider Transactions


DateNameRoleActivityValue
May 05, 2025Cline Christopher R. CHIEF FINANCIAL OFFICERSell$37.55K
May 05, 2025Dube Eric M CHIEF EXECUTIVE OFFICERSell$398.35K
May 05, 2025Heerma Peter CHIEF COMMERCIAL OFFICERSell$37.28K
May 05, 2025ROTE WILLIAM E. Chief Research OfficerSell$67.32K
May 05, 2025REED ELIZABETH E Chief Legal Officer and GCSell$103.57K

Insider Transactions Trends


DateBuySell
2025 Q2-6
2025 Q1-26
2024 Q4-4
2024 Q3-9
2024 Q2-1

TVTX Ownership FAQ


Who Owns Travere Therapeutics?

Travere Therapeutics shareholders are primarily institutional investors at 5.13%, followed by 0.70% insiders and 94.17% retail investors. The average institutional ownership in Travere Therapeutics's industry, Biotech Stocks , is 63.96%, which Travere Therapeutics falls below.

Who owns the most shares of Travere Therapeutics?

Travere Therapeutics’s largest shareholders are Blackrock funding, inc. /de (8.02M shares, 10.31%), Blackrock (7.64M shares, 9.86%), and Armistice capital (7.36M shares, 9.46%). Together, they hold 29.63% of Travere Therapeutics’s total shares outstanding.

Does Blackrock own Travere Therapeutics?

Yes, BlackRock owns 9.86% of Travere Therapeutics, totaling 7.64M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 62.84M$. In the last quarter, BlackRock decreased its holdings by -152K shares, a -1.95% change.

Who is Travere Therapeutics’s biggest shareholder by percentage of total assets invested?

Rock springs capital management lp is Travere Therapeutics’s biggest shareholder by percentage of total assets invested, with 3.30% of its assets in 4.97M Travere Therapeutics shares, valued at 86.64M$.

Who is the top mutual fund holder of Travere Therapeutics shares?

Delaware Small Cap Core I is the top mutual fund holder of Travere Therapeutics shares, with 4.42% of its total shares outstanding invested in 3.45M Travere Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools